VKTX
insider transactionsViking Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-344.3K
4.5K buy · 348.7K sell
Net value · 365d
-$11.3M
$149.9K in · $11.5M out
Sentiment · 365d
Net selling
1% buying · 99% selling
Open-market trades · 365d
13
4.5K buy · 348.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Chief Medical Officer
$0
190.0K sh
Own New
-
Buy·P
Chief Commercial Officer
$149.9K
4.5K sh · $33.50
Own New
-
Grant·A
Chief Commercial Officer
$0
180.0K sh
Own New
-
Sell·S
Greg Zante KEY
Chief Financial Officer
$48.1K
1.5K sh · $32.09
Own -1%
-
Sell·S
Greg Zante KEY
Chief Financial Officer
$352.6K
10.3K sh · $34.24
Own -5%
-
Sell·S
Greg Zante KEY
Chief Financial Officer
$464.0K
13.9K sh · $33.38
Own -6%
-
Sell·S
Greg Zante KEY
Chief Financial Officer
$1.0M
32.0K sh · $32.30
Own -13%
-
Sell·S
Chief Operating Officer
$56.1K
1.6K sh · $35.07
Own -0%
-
Sell·S
Chief Operating Officer
$359.3K
10.5K sh · $34.22
Own -2%
-
Sell·S
Chief Operating Officer
$453.9K
13.6K sh · $33.37
Own -3%
-
Sell·S
Chief Operating Officer
$1.0M
32.0K sh · $32.29
Own -7%
-
Sell·S
Brian Lian KEY
President & CEO
$224.4K
6.4K sh · $35.07
Own -0%
-
Sell·S
Brian Lian KEY
President & CEO
$1.4M
41.3K sh · $34.22
Own -2%
-
Sell·S
Brian Lian KEY
President & CEO
$1.8M
53.3K sh · $33.38
Own -2%
-
Sell·S
Brian Lian KEY
President & CEO
$4.3M
132.5K sh · $32.29
Own -5%
-
Grant·A
Greg Zante KEY
Chief Financial Officer
$0
91.0K sh
Own New
-
Grant·A
Greg Zante KEY
Chief Financial Officer
$0
32.0K sh
Own +15%
-
Grant·A
Greg Zante KEY
Chief Financial Officer
$0
41.0K sh
Own +23%
-
Grant·A
Director
$0
20.4K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +33%
-
Grant·A
Director
$0
20.4K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +10%
-
Grant·A
Director
$0
20.4K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +254%
-
Grant·A
Chief Operating Officer
$0
91.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
32.0K sh
Own +7%
-
Grant·A
Chief Operating Officer
$0
41.0K sh
Own +10%
-
Grant·A
Director
$0
20.4K sh
Own New
-
Grant·A
Director
$0
3.1K sh
Own +7%
-
Grant·A
Brian Lian KEY
President & CEO
$0
176.3K sh
Own New
-
Grant·A
Brian Lian KEY
President & CEO
$0
224.1K sh
Own +9%
-
Grant·A
Brian Lian KEY
President & CEO
$0
78.4K sh
Own +3%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Hubert C Chen | Grant A | 190.0K | $0 |
| Mar 10, 2026 | Neil William Aubuchon | Buy P | 4.5K | $149.9K |
| Jan 12, 2026 | Neil William Aubuchon | Grant A | 180.0K | $0 |
| Jan 5, 2026 | Greg Zante KEY | Sell S | 1.5K | $48.1K |
| Jan 5, 2026 | Greg Zante KEY | Sell S | 10.3K | $352.6K |
| Jan 5, 2026 | Greg Zante KEY | Sell S | 13.9K | $464.0K |
| Jan 5, 2026 | Greg Zante KEY | Sell S | 32.0K | $1.0M |
| Jan 5, 2026 | Marianna Mancini | Sell S | 1.6K | $56.1K |
| Jan 5, 2026 | Marianna Mancini | Sell S | 10.5K | $359.3K |
| Jan 5, 2026 | Marianna Mancini | Sell S | 13.6K | $453.9K |
| Jan 5, 2026 | Marianna Mancini | Sell S | 32.0K | $1.0M |
| Jan 5, 2026 | Brian Lian KEY | Sell S | 6.4K | $224.4K |
| Jan 5, 2026 | Brian Lian KEY | Sell S | 41.3K | $1.4M |
| Jan 5, 2026 | Brian Lian KEY | Sell S | 53.3K | $1.8M |
| Jan 5, 2026 | Brian Lian KEY | Sell S | 132.5K | $4.3M |
| Jan 2, 2026 | Greg Zante KEY | Grant A | 91.0K | $0 |
| Jan 2, 2026 | Greg Zante KEY | Grant A | 32.0K | $0 |
| Jan 2, 2026 | Greg Zante KEY | Grant A | 41.0K | $0 |
| Jan 2, 2026 | Matthew J Singleton | Grant A | 20.4K | $0 |
| Jan 2, 2026 | Matthew J Singleton | Grant A | 3.1K | $0 |
| Jan 2, 2026 | Charles A Rowland Jr | Grant A | 20.4K | $0 |
| Jan 2, 2026 | Charles A Rowland Jr | Grant A | 3.1K | $0 |
| Jan 2, 2026 | Sarah Kathryn Rouan | Grant A | 20.4K | $0 |
| Jan 2, 2026 | Sarah Kathryn Rouan | Grant A | 3.1K | $0 |
| Jan 2, 2026 | Marianna Mancini | Grant A | 91.0K | $0 |
| Jan 2, 2026 | Marianna Mancini | Grant A | 32.0K | $0 |
| Jan 2, 2026 | Marianna Mancini | Grant A | 41.0K | $0 |
| Jan 2, 2026 | Lawson Macartney | Grant A | 20.4K | $0 |
| Jan 2, 2026 | Lawson Macartney | Grant A | 3.1K | $0 |
| Jan 2, 2026 | Brian Lian KEY | Grant A | 176.3K | $0 |
| Jan 2, 2026 | Brian Lian KEY | Grant A | 224.1K | $0 |
| Jan 2, 2026 | Brian Lian KEY | Grant A | 78.4K | $0 |
About VKTX insider trading
This page tracks insider transactions for Viking Therapeutics, Inc. (VKTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.